Codethink Achieves Positive Functional Safety Assessment to IEC 61508 and ISO 26262 Standards for the Eclipse Trustable Software Framework
30.10.2025 10:04:00 CET | Business Wire | Press Release
Codethink announced that it has successfully achieved a positive and complete Functional Safety Assessment for the Eclipse Trustable Software Framework (TSF).
Performed by exida, a globally recognised authority in functional safety, the assessment was conducted in accordance with IEC 61508 requirements, with domain experts ensuring full alignment and compatibility with ISO 26262, the automotive industry’s functional safety standard. The evaluation represents a major milestone in Codethink’s mission to transform how the world engineers, verifies, and trusts software.
According to the assessment, “considering the process objectives of both IEC 61508 and ISO 26262, the specification of Trustable [Trustable Software Framework] and the reference implementation that maps Trustable tenets and assertions to the objectives in IEC 61508, it is determined that Trustable sets out an approach to software development which meets and in many cases exceeds the rigor and expectations established for software in IEC 61508 at SIL 3.”
The report further concludes that “organizations that attempt to implement TSF according to the reference model may proceed confidently that they will be able to measure their progress towards a future certification attempt safe in the knowledge that the requirements for a successful assessment will be met.”
“This assessment validates that trust in software, especially open source, can be both measurable and auditable,” said Paul Sherwood, Codethink’s Chairman. “Functional safety is no longer a checkbox, it’s a design principle. The Eclipse Trustable Software Framework gives organizations the means to demonstrate integrity at every stage of development.”
The Eclipse Trustable Software Framework defines six tenets, Provenance, Construction, Changes, Expectations, Results, and Confidence, each mapped to the objectives of IEC 61508 and ISO 26262. This structure enables companies to align open source and proprietary development with safety-critical rigor, ensuring traceability and reproducibility from concept to deployment.
By embedding these principles directly into everyday engineering workflows, TSF bridges the long-standing divide between compliance and innovation. It provides regulators, insurers, and developers with a shared language for evaluating and improving the trustability of complex software systems.
This Functional Safety Assessment follows a series of Codethink milestones, including the contribution of the TSF to the Eclipse Foundation, as well as the successful baseline safety assessment of CTRL OS using the TSF.
“We remain focused on the real work of engineering safety, security, and reliability, not simply collecting certificates,” added Sherwood. “At its core, this is about trust: Trust that software will behave as intended, and trust that our systems and mitigations will perform when it matters most.”
Download the TSF Functional Safety Assessment report at https://www.codethink.co.uk/trustable-software-framework.html.
About Codethink
Codethink is a world-class provider of critical, high-performance software projects and solutions for international-scale companies in a range of industries including Automotive, Finance, Medical, and IoT. Headquartered in Manchester, UK, Codethink has pioneered software industry thinking around concepts of trustable software, working to improve the quality of software engineering.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251030029293/en/
Contacts
Media contact: press@codethink.co.uk
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom